Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Gilead Sciences (GILD)

Gilead Sciences Q2 revenue up 10% to $7.8 billion; $(8.45) per share loss

Mixed Impact 4 of 5 earnings Written later

Gilead reported second quarter 2026 total revenues of $7.8 billion, up 10% from a year earlier, and raised its full-year 2026 product sales guidance. The company posted a GAAP diluted loss of $(8.45) per share, driven by $11.2 billion of acquired in-process R&D expenses tied to recent acquisitions, and its full-year GAAP loss per share guidance was widened.

Key points

  • Total revenues rose 10% to $7.8 billion; HIV product sales rose 12% to $5.7 billion.
  • GAAP diluted loss per share was $(8.45), compared with diluted earnings of $1.56 a year earlier, mainly due to $(9.08) per share of acquired IPR&D and tax expenses.
  • Full-year 2026 GAAP diluted loss per share guidance is $(3.75) to $(3.40), down from the prior $(3.25) to $(2.85); product sales guidance is $30.1 billion to $30.4 billion, up from $30.0 billion to $30.4 billion.
  • Cash, cash equivalents and marketable debt securities were $3.2 billion at June 30, 2026, compared with $10.6 billion at December 31, 2025.

The filing

CompanyGilead Sciences (GILD)
Form8-K, current report
Filed with the SECAug 4, 2026, 4:03 PM ET
Accession number0000882095-26-000028

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.